Not content with a $1.2 billion licensing deal for Biohaven Pharma's oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer's ...
Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine ...
Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that Biohaven knowingly submitted or caused false claims to be submitted to Medicaid and other federal health care ...
Biohaven Ltd. (NYSE:BHVN – Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 9,440,000 shares, a decline of ...
After hours: February 21 at 6:53:05 PM EST ...
A growing cohort of biotechs, from Biohaven to Neurocrine to Jazz, hope research on ion channels will bring them new drugs and big business — much like it has done for Vertex.